These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 14675982)

  • 1. Comparative analysis of oestrogen and raloxifene effects on the phospholipid composition of high density lipoproteins in healthy postmenopausal women.
    Piperi C; Kalofoutis C; Papapanagiotou A; Skenderi C; Kalofoutis A
    J Obstet Gynaecol; 2004 Jan; 24(1):52-7. PubMed ID: 14675982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of hormone replacement therapy on the phospholipid composition of high density lipoproteins in postmenopausal women.
    Papapanagiotou A; Koufali MM; Zachari A; Charalabidou C; Kalofoutis A
    J Obstet Gynaecol; 2001 Jan; 21(1):56-61. PubMed ID: 12521913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women.
    Piperi C; Kalofoutis C; Skenderi K; Economidou O; Kalofoutis A
    J Obstet Gynaecol; 2004 Jun; 24(4):414-9. PubMed ID: 15203583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
    Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
    Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of raloxifene treatment on the phenotype of blood monocytes.
    Boudjeltia KZ; Durez P; Oberweis D; Guillaume M; Remacle C; Cauchie P; Vanhaeverbeek M; Brohée D; Ducobu J; Gregoir C
    Can J Physiol Pharmacol; 2010 May; 88(5):601-5. PubMed ID: 20555430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
    Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
    Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene.
    Tommaselli GA; Di Carlo C; Di Spiezio Sardo A; Bifulco G; Cirillo D; Guida M; Capasso R; Nappi C
    Menopause; 2006; 13(4):660-8. PubMed ID: 16837888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.
    Lasco A; Gaudio A; Morini E; Morabito N; Nicita-Mauro C; Catalano A; Denuzzo G; Sansotta C; Xourafa A; Macrì I; Frisina N
    Menopause; 2006; 13(5):787-92. PubMed ID: 16912660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
    Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
    Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of estrogens and progestogens on the lipid profile in postmenopausal hypogonadism].
    García L; Hernández I; Cervera Aguilar R; Ayala AR
    Ginecol Obstet Mex; 2001 Sep; 69():351-4. PubMed ID: 11816532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: a randomized, placebo-controlled clinical trial.
    Engin-Ustün Y; Ustün Y; Meydanli MM; Kafkasli A
    Gynecol Endocrinol; 2006 Dec; 22(12):676-9. PubMed ID: 17162709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
    Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
    Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
    Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
    Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women.
    Vogelvang TE; Mijatovic V; Kenemans P; Schalkwijk CG; van der Mooren MJ
    Am J Cardiol; 2004 Nov; 94(9):1205-8. PubMed ID: 15518626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence of improved serum fatty acid profile of postmenopausal women receiving atorvastatin and raloxifene.
    Piperi C; Zisaki K; Skenderi K; Kalofoutis C; Kalofoutis A
    J Obstet Gynaecol; 2005 Jul; 25(5):476-81. PubMed ID: 16183584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic dosages of raloxifene do not modify myeloperoxidase and F2alpha-isoprostane levels in postmenopausal women.
    Oviedo PJ; Hermenegildo C; Tarín JJ; Cano A
    Fertil Steril; 2005 Dec; 84(6):1789-92. PubMed ID: 16359994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
    Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.